

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

COMPLETE IF KNOWN

| | |
|-------------------------------|-------------------|
| Application Number | 10/573,108 |
| Filing Date | March 23, 2006 |
| First Named Inventor | Wallace T. Ashton |
| Group Art Unit | To be Assigned |
| Examiner Name | To be Assigned |
| Attorney Docket Number | 21562P |

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 5 |
|-------|---|----|---|

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
|--------------------|----------|-------------------------|-------------------|-------------------------|---|---|
| | | Office | Number | Kind Code (if known) | | |
| | 8 | PCT | WO 03/002017 A2 | | MERCK & CO., INC. | 10/09/2003 |
| | 9 | PCT | WO 03/000180 A2 | | MERCK & CO., INC. | 01/03/2003 |
| | 10 | PCT | WO 03/000181 A2 | | MERCK & CO., INC. | 01/03/2003 |
| | 11 | PCT | WO 03/000181 A2 | | MERCK & CO., INC. | 01/03/2003 |
| | 12 | PCT | WO 02/070430 A1 | | MERCK & CO., INC. | 10/03/2002 |
| | 13 | PCT | WO 2004/007468 A1 | | MERCK & CO., INC. | 01/22/2004 |
| | 14 | PCT | WO 2004/032830 A2 | | MERCK & CO., INC. | 04/22/2004 |
| | 15 | PCT | WO 2004/050022 A2 | | MERCK & CO., INC. | 06/17/2004 |
| | 16 | PCT | WO 2004/050266 A1 | | MERCK & CO., INC. | 07/15/2004 |
| | 17 | PCT | WO 2004/064778 A2 | | MERCK & CO., INC. | 08/03/2004 |

**Examiner
Signature**

/Fiona T. Powers/

Date Considered

03/27/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 7/12/2005

Note: References that are crossed out are not of record in the file.

(use as many sheets as necessary)

COMPLETE IF KNOWN

| | |
|-------------------------------|--------------------------|
| Application Number | 10/573,108 |
| Filing Date | March 23, 2006 |
| First Named Inventor | Wallace T. Ashton, et al |
| Group Art Unit | To Be Assigned |
| Examiner Name | To Be Assigned |
| Attorney Docket Number | 21562P |

| | | | |
|-------|---|----|---|
| Sheet | 2 | of | 5 |
|-------|---|----|---|

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
|--------------------|----------|-------------------------|-------------------|-------------------------|---|---|
| | | Office | Number | Kind Code (if known) | | |
| | 18 | PCT | WO 2004/069162 A2 | | MERCK & CO., INC. | 08/19/2004 |
| | 19 | PCT | WO 02/02560 A2 | | NOVO NORDISK A/S | 01/10/2002 |
| | 20 | PCT | WO 01/96295 A2 | | NOVARTIS AG | 12/20/2001 |
| | 21 | PCT | WO 01/96295 A3 | | NOVARTIS AG | 12/20/2001 |
| | 22 | PCT | WO 01/34594 A1 | | Guilford Pharmaceuticals, Inc. | 05/17/2001 |
| | 23 | PCT | WO 00/34241 | | NOVARTIS AG | 06/15/2000 |
| | 24 | PCT | WO 98/19998 A2 | | NOVARTIS AG | 05/14/1998 |
| | 25 | PCT | WO 98/19998 A3 | | NOVARTIS AG | 05/14/1998 |
| | 26 | PCT | WO 97/40832 | | Hansknoll-Institut Fur Naturstoff-Forschung E.V. | 11/06/1997 |
| | 27 | PCT | WO 03/000180 A3 | | MERCK & CO., INC. | 01/03/2003 |

**Examiner
Signature**

/Fiona T. Powers/

Date Considered

03/27/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

| | |
|------------------------|--------------------------|
| Application Number | 10/573,108 |
| Filing Date | March 23, 2006 |
| First Named Inventor | Wallace T. Ashton, et al |
| Group Art Unit | To Be Assigned |
| Examiner Name | To Be Assigned |
| Attorney Docket Number | 21562P |

Sheet 5 of 5

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. | Include name of the author, title, date, page(s), volume-issue number(s) and place of publication. |
|--------------------|----------|---|
| | 43 | J. J. Holst, "Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors", Expert Opin. Emerg. Drugs, Vol. 9(1) pp. 155-166(2004). |
| | 44 | C. F. Deacon, et al., "Inhibitors of dipeptidyl peptidase IV: A Novel Approach for the Prevention and Treatment of Type 2 Diabetes?", Expert Opin. Investig. Drugs, Vol. 13(9) pp. 1091-1102(2004). |
| | 45 | K. Augustyns et al., " Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes", Expert Opin. Ther. Patents, Vol. 13(4), pp. 499-510(2003). |
| | 46 | Novartis AG: WO0034241, "Novel N-substituted-2-Cyanopyrrolidines as Potent Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Non-Insulin-Dependent Diabetes Mellitus", Exp. Opin. Ther. Patents, Vol. 10(12), pp. 1937-1942 (2000). |
| | 47 | D. J. Orucker, "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes", Exp. Opin Invest. Drugs, Vol.12, pp. 87-100 (2004). |
| | 48 | T. P. Vahl & D. A. D'Alessio, "Gut peptides in the treatment of diabetes mellitus" Exp. Opin. Invest. Drugs, Vol. 13, pp. 177-188 (2004). |
| | 49 | L. B. Knudsen, "Glucagon-like peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes", J. Med. Chem, Vol. 47, pp. 4128-4134 (2004). |
| | 50 | A. E. Weber, "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes", J. Med. Chem, Vol. 47, pp. 4135-4141 (2004). |
| | 51 | J. J. Holst and C. F. Deacon, "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus", Curr. Opin Pharmacology, Vol. 4, pp. 589-596 (2004). |
| | 52 | C. F. Deacon, "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1", Diabetes, Vol. 53, pp. 2181-2189 (2004). |
| | 53 | K. Augustyns, et al., "Inhibitors of proline-specific dipeptidyl peptidase: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes", Expert Opin. Ther. Patents, Vol. 15(10), pp. 1387-1407 (2005). |
| | 54 | Hans-Ulrich Demuth, et al., " Type 2 diabetes - Therapy with dipetidyl peptidase IV inhibitors", Biochimica et Biophysica Acta, Vol. 1751, pp., 33-44 (2005). |
| | | |
| | | |
| | | |

Examiner Signature

/Fiona T. Powers/

Date Considered

03/27/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005